△通讯作者：张达颖：[e-mail]；鄢毅：[e-mail]

CLINICAL OBSERVATION OF ZHENGQINGFENGTONGNING SUSTAINED-RELEASE TABLETS COMBINED WITH GABAPENTIN IN TREATING SUBACUTE HERPES ZOSTER NEURALGIA

摘要:

目的：探讨正清风痛宁缓释片联合加巴喷丁治疗亚急性期带状疱疹后性神经痛的临床疗效及安全性。方法：收集我院疼痛科2016年12月至2018年12月住院诊断的60例亚急性期带状疱疹后神经痛患者(病程4 ≤12周),随机分为对照组(C)和试验组(E组)(每组30例),两组患者均接受口服加巴喷丁胶囊,静脉点滴神经妥乐平治疗。E组同时加服正清风痛宁缓释片。采用视觉模拟评分(visual analogue score, VAS)评估两组患者治疗前及治疗后第1、4、7、14天,1月、2月时的疼痛强度,评价疼痛缓解情况；采用匹兹堡睡眠质量指数(Pittsburgh sleep quality index, PSQI)评估两组患者在治疗前及治疗1月、2月时的睡眠情况,同时观察两组患者治疗过程中的不良反应。结果：治疗后两组患者VAS、PSQI评分较治疗前均有明显降低。E组VAS评分从治疗后7天开始较对照组明显降低。PSQI评分从治疗后1月开始E组较C组明显降低。两组患者均未见明显不良反应发生。结论：正清风痛宁缓释片联合加巴喷丁对于亚急性期带状疱疹后神经痛具有较好的中远期效果,安全性高,可能是临床亚急性疱疹性神经痛或PHN治疗的一个有效方案。

Abstract:

Objective: To investigate the clinical efficacy and safety of Zhengqingfengtongning sustained-release tablets combined with gabapentin in the treatment of subacute postherpetic neuralgia. Methods: 60 subacute post-herpetic neuralgia patients (duration of disease 4 ≤ 12 weeks) diagnosed in pain department of our hospital from December 2016 to December 2018 were randomly divided into control group (C) and test group (E) (30 cases in each group). both groups of patients received oral gabapentin capsule and intravenous drip of neurotropin. Group E also received Zhengqingfengtongning sustained-release tablets. Visual analogue score, VAS) was used to evaluate the pain intensity of the two groups of patients before treatment and on the 1st, 4th, 7th, 14th, January and February after treatment, and to evaluate the pain relief. Pittsburgh Sleep Quality Index (PSQI) was used to evaluate the sleep status of the two groups of patients before treatment and in January and February of treatment. Meanwhile, adverse reactions in the treatment process of the two groups of patients were observed. Results: After treatment, VAS and PSQI scores of the two groups were significantly lower than before treatment. VAS score in group E was significantly lower than that in control group from 7 days after treatment. PSQI score in group E was significantly lower than that in group C from 1 month after treatment. No obvious adverse reactions occurred in both groups of patients. Conclusion: Zhengqingfengtongning sustained-release tablets combined with gabapentin have good long-term and medium-term effects on subacute post-herpetic neuralgia with high safety, which may be an effective scheme for clinical subacute herpetic neuralgia or PHN treatment.